FLGR-242 / Follistatin: Everything You Need To Know Before You Buy

#Follistatin #FLGR242 #Peptides FLGR-242 is a modified follistatin product being promoted for myostatin inhibition with claims of up to 1.5 lbs of skeletal muscle per week. The science behind myostatin inhibition is legitimate and backed by decades of published research, but this specific compound has never been tested in a human clinical trial, and every pharmaceutical company that tried to build a myostatin inhibitor hit the same wall. In this video I break down the full mechanism, both modifications to the molecule, and what the published data actually supports versus what remains completely unproven. In this video I walk you through: 🔬 What myostatin is and why blocking it matters 🔬 The FS I-I variant and what removing activin binding actually does ⚠️ Why Regeneron's 999-patient COURAGE trial changes the activin conversation 💉 The albumin-binding half-life extension claim and what's unproven 🏭 The pharmaceutical graveyard: every major company that tried and failed 📊 SubQ protein injection vs gene therapy: fundamentally different approaches 📋 Published and anecdotal follistatin injection data from the past decade ⚠️ Cancer, tendon, cardiac, and cessation concerns 🏋️ Why exercise is mechanistically non-optional 💰 Conflict of interest disclosure ⚕️ Disclaimer: This video is for informational purposes only and not medical advice. Always consult your physician before starting any peptide or compound protocol. 🕐 Chapters 0:00 Introduction 1:10 What Is Myostatin and Why It Matters 1:50 Human Mutations and Gene Therapy Proof 3:00 What Is FLGR-242: The Two Modifications 3:10 Modification 1: The FS I-I Variant 3:35 The Activin Paradox: Regeneron COURAGE Trial 4:52 Modification 2: Albumin-Binding Half-Life Claim 5:40 Who Is Making These Claims 6:42 The Pharmaceutical Graveyard 7:32 SubQ Protein vs Gene Therapy: The Delivery Gap 8:30 Actual Follistatin Injection Data 9:30 Safety: Cancer, Tendons, Cardiac, Cessation 10:22 Exercise Is Non-Optional 10:48 Dosing Claims vs Published Evidence 11:02 Final Assessment 11:45 Josh's Take: Why This Is a No-Go 12:20 Community and Resources 📱 Free Peptide & Supplement Tracker App: https://tracker.joshholyfield.com 👥 Join my FREE Skool community: For men: https://www.skool.com/jh-iron-forge-b... For women: https://www.skool.com/powerhouse-fitn... 🏋️ Looking for personalized coaching and accountability? https://programs.theironforge.us/survey Drop your questions in the comments and subscribe for more evidence-based breakdowns on supplements, peptides, and proven methods to get lean and strong the right way. Tags / Keywords FLGR-242, follistatin, FLGR-242 review, follistatin 344, myostatin inhibitor, myostatin blocker, FLGR-242 follistatin, Jay Campbell FLGR-242, BioLongevity Labs, follistatin peptide, myostatin inhibition muscle growth, FLGR 242 results, follistatin injection, FS I-I variant, bimagrumab, COURAGE trial myostatin, myostatin blocker results, follistatin before and after, peptide muscle growth, myostatin gene therapy, ActRIIB, follistatin side effects ____________________ Socials: Facebook:   / joshholyfieldpd   Instagram:   / josh.holyfield   TikTok:   / josh_holyfield   Youtube:    / joshholyfieldfitness   Blog: https://joshholyfield.com/blogs/news ====================================================== Josh Holyfield - For all business inquiries contact [email protected] This video is not to be reproduced without prior authorization. The original YouTube video may be distributed & embedded if required. 📚 References 1. Schuelke et al. (2004) NEJM — MSTN mutation case https://doi.org/10.1056/NEJMoa040933 2. Mendell et al. (2015) Mol Ther — Follistatin gene therapy BMD https://doi.org/10.1038/mt.2014.200 3. Kota et al. (2009) Sci Transl Med — NHP follistatin gene therapy https://doi.org/10.1126/scitranslmed.... 4. Sidis et al. (2006) Endocrinology — FS I-I variant characterization https://doi.org/10.1210/en.2006-0089 5. Lach-Trifilieff et al. (2014) MCB — Activin + myostatin blockade https://doi.org/10.1128/MCB.01307-13 6. McPherron et al. (1997) Nature — Myostatin discovery https://doi.org/10.1038/387083a0 7. Mendias et al. (2008) PNAS — Tendon brittleness in MSTN-/- mice https://doi.org/10.1073/pnas.0707069105 8. Suh et al. (2020) PNAS — Follistatin/GDF11/bone https://doi.org/10.1073/pnas.1916034117